FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 260 filers reported holding FATE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $823,103 | -3.2% | 388,256 | +117.3% | 0.00% | -33.3% |
| Q2 2023 | $850,360 | +789.4% | 178,647 | +965.0% | 0.00% | – |
| Q1 2023 | $95,612 | -98.1% | 16,774 | -96.6% | 0.00% | -100.0% |
| Q4 2022 | $4,964,098 | +860.2% | 491,982 | +2030.7% | 0.03% | +800.0% |
| Q3 2022 | $517,000 | -32.7% | 23,090 | +78.2% | 0.00% | -70.0% |
| Q3 2021 | $768,000 | -60.7% | 12,958 | -42.5% | 0.01% | -54.5% |
| Q2 2021 | $1,956,000 | +153.7% | 22,536 | +140.9% | 0.02% | +83.3% |
| Q1 2021 | $771,000 | +188.8% | 9,354 | -31.5% | 0.01% | +50.0% |
| Q4 2019 | $267,000 | – | 13,648 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |